Genmab — September 2017

[Solsen]

https://www.pubfacts.com/author/Kate+Sasser Lidt af det hun har medvirket til.

[royal]

Er hun ikke "bare" flyttet fra Janssen? Ikke meget Rachel talte om Arzerra.

[royal]

Interviewet med Rachel viser tydeligt hvorfor Genmab forbliver selvstændigt.

[bibob]

God morgen.

[bibob]

ESMO : 8 sep. kl 16. https://cslide.ctimeetingtech.com/library/esmo/browse/search/Kop#2Bb5p0xs Og 10 sep. kl 13.15. https://cslide.ctimeetingtech.com/library/esmo/browse/search/Kop#2Bb5p0xs

[bibob]

https://cslide.ctimeetingtech.com/library/esmo/browse/search/Kop#2Bb5p0xs

[Mogan]

God morgen

[bibob]

Rod med IPAD. Ved ikke om linkene virker.

[bibob]

https://cslide.ctimeetingtech.com/library/esmo/browse/search/Kop#2Bb3g0jp

[Mogan]

bibob: tak, de virker hos mig

[Helge_LarsenPI-redaktør]

God morgen og tak for link.

[bibob]

[JKY_VH]

God morgen og tak bibob

[E_L]

aren't these the same links as we discussed on Thursday morning?

[bibob]

I really dont know. Just seeing them

[E_L]

no worries bibob, better too often as not at all;
enjoy you coffee in the sun

[E_L]

Cellectis Reports Clinical Hold of UCART123 Studies http://www.businesswire.com/news/home/20170904005410/en/

[Jedi]

More on UCART from Celletics http://www.cellectis.com/en/products/ucarts/ apparently, the next generation CAR-T is not quite ready yet...

[Jedi]

The Cellectis UCART123 target CD123, different from the fatalities of CAR-T targeting CD19, but same sad result

[Sukkeralf]

But we also saw Janssen/Genmab having problems with CD123/CD3 - probably not easy to engage the T-cell and av
oid adverse effects